They evaluated PD-L1 mRNA expression levelsin plasma EVs from melanoma and NSCLC patients during nivolumab and pembrolizumab therapy.After 2 months of treatment, the EV PD-L1 mRNA copy numbers were significantly decreasedin responders but remained unchanged in nonresponders[134]. This evidence concerns the gene CD274 and melanoma.